Skip to main content

Rapid diagnosis of preeclampsia at the point-of-care

Objective

MOMM Diagnostics conceives a new generation of in-vitro diagnostic tests for early diagnosis of preeclampsia. Preeclampsia remains to this day one of the leading causes for maternal mortality. Early diagnosis is therefore vital to minimize complications and prepare adequately for birth. The startup is developing a solution using microscale solid-state sensors for electrical detection of biomarkers in blood, which would allow the detection of multiple biomarkers, using a single-use cartridge and a hand-held reader for diagnosis of the condition directly where the patients are being taken care of. Technology originating from results of the FETOPEN project RECORD-IT (Project ID: 664786) has shown promising innovation potential. MOMM Diagnostics aims to verify this potential for commercialization by assessing its competitiveness for point of care applications. The technology promises an increased signal to noise ratio at a smaller form factor and lower cost compared to commercially available technologies. The FET Innovation Launchpad will help to consolidate the intellectual property rights and develop a demonstrator to approach investors.

Field of science

  • /social sciences/sociology/demography/fertility
  • /social sciences/sociology/demography/mortality

Call for proposal

H2020-FETOPEN-2018-2019-2020-03
See other projects for this call

Funding Scheme

CSA - Coordination and support action

Coordinator

MOMM DIAGNOSTICS GMBH
Address
Hochbergerstrasse 60C
4057 Basel
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 72 000

Participants (1)

EIDGENOSSISCHE MATERIALPRUFUNGS- UND FORSCHUNGSANSTALT
Switzerland
EU contribution
€ 28 000
Address
Ueberlandstrasse 129
8600 Dubendorf
Activity type
Higher or Secondary Education Establishments